100 Black Men Revamp Med School Summer Camp

100 Black Men Revamp Med School Summer Camp

To saline or not to saline

Is it really benefical to instill 3 cc of mucomyst into and endotracheal tube and then suction the solution immediately after the instillation? What the heck is going on with that?

Let's take a look at Mucomyst (N-acetylcyteine): N-acetylcyteine is a derivative of a naturally occuring amino acid, L-cysteine and it contains sulfhydryl group (-SH) which have the ability to cleave disulfide bonds in proteins. The most important variables at affect the mucolytic and proteolytic effects of Mucomyst at pH and time of incubation. Studies demonstrate that there is about a 20% improvement in the effectiveness of Mucomyst when the pH is 8.0 - 9.0 as compared to a pH below 7.5 with an incubation period of 60 minutes.

Read the article: Clinical Experiences with Acetylcysteine as a Mucolvtic Agent.

Respiratory Pharmacology made easy

http://ppahs.org/2014/05/08/harold-oglesby-noted-opioid-safety-expert-and-patient-safety-advocate-joins-physician-patient-alliance-for-health-safety-advisory-board/

Fiducial Placement and Pleural Dye Marking wtih ENB

http://www.youtube.com/watch?v=0YbZDYR1zl4&feature=related

STEREOTACTIC RADIOTHERAPY

WITH REAL-TIME TUMOR TRACKING

FOR NON-SMALL CELL LUNG

CANCER: CLINICAL OUTCOME

 

NC van der Voort van Zyp, J-B Prevost, MS Hoogeman,

J Praag, B van der Holt, PC Levendag, RJ van Klaveren,

P Pattynama, JJ Nuyttens




Purpose

To report the clinical outcome of treatment using real-time tumor tracking for 70 patients

with inoperable stage I non-small cell lung cancer (NSCLC).

Methods

Seventy inoperable patients with peripherally located early stage NSCLC were treated with

45 or 60 Gy in 3 fractions using the CyberKnife. Pathology was available in 51% of patients.

Thirty-nine patients had a T1-tumor and thirty-one had a T2-tumor. Markers were placed

using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk

of pneumothorax.

Results

The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared

to 78% for patients treated with a total dose of 45 Gy (p=0.197). All local recurrences (n=4)

occurred in patients with T2-tumors. Overall survival for the whole group at two years was

62% and the cause speci

fi c survival was 85%. The median follow-up was 15 months. Grade

3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade

3 toxicity occurred in 7 patients (10%). No grade 4 or 5 toxicity occurred.

Conclusion

Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in 3 fractions for

NSCLC patients treated with the real-time tumor tracking. Toxicity was low.

Curosurf admin

http://www.youtube.com/watch?v=c7XoHIjMtm0